Natus Medical (BABY) Getting Somewhat Positive News Coverage, Study Shows

Headlines about Natus Medical (NASDAQ:BABY) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natus Medical earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 47.7394028903043 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently weighed in on BABY. BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Benchmark Co. reissued a “buy” rating and set a $48.00 price target (down from $55.00) on shares of Natus Medical in a research report on Monday, May 1st. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Finally, TheStreet lowered Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $45.00.

Shares of Natus Medical (NASDAQ BABY) traded down 3.70% during trading on Friday, hitting $32.50. The stock had a trading volume of 360,673 shares. Natus Medical has a 52 week low of $32.45 and a 52 week high of $44.39. The company’s 50 day moving average price is $36.08 and its 200 day moving average price is $36.52. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of 56.33 and a beta of 0.93.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.01. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The firm had revenue of $122.20 million during the quarter, compared to analysts’ expectations of $121.99 million. During the same quarter in the prior year, the company earned $0.39 EPS. The company’s revenue was up 27.3% compared to the same quarter last year. Analysts predict that Natus Medical will post $1.70 earnings per share for the current year.

In related news, Director Doris Engibous sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $32.68, for a total transaction of $163,400.00. Following the completion of the transaction, the director now owns 22,650 shares in the company, valued at approximately $740,202. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider James B. Hawkins acquired 6,000 shares of Natus Medical stock in a transaction that occurred on Wednesday, May 31st. The shares were purchased at an average price of $33.81 per share, with a total value of $202,860.00. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Natus Medical (BABY) Getting Somewhat Positive News Coverage, Study Shows” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

What are top analysts saying about Natus Medical Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natus Medical Incorporated and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit